Use of triglyceride oils containing γ-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease
US7935729B2 · kind B2 · utility
17Cited by
83References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2004 |
| Grant date | May 3, 2011 |
| Priority date | — |
| Expiry date | Feb 21, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Method for treating a patient in need of therapy for a neurodegenerative disease by administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linolenic acid residues as triglyceride ester. The ratio of γ-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of γ-linolenic acid residues at the sn-2 position is at least 18%. The oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.